Magnesium intake and bladder cancer incidence and mortality in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial
Principal Investigator
About this CDAS Project
Study
PLCO
(Learn more about this study)
Project ID
PLCO-736
Initial CDAS Request Approval
Feb 17, 2021
Title
Magnesium intake and bladder cancer incidence and mortality in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial
Summary
Urothelial carcinoma of the bladder is an extremely prevalent genitourinary malignancy. It represents the second most frequently reported genitourinary system cancer in the United States, with a male to female ratio of about 3:4.Evidence suggests a role for the ability of diet to modulate inflammation in the etiology of this disease.So, a dietary pattern approach that provides perceptions into the complex interactions between dietary components can guide dietary intervention strategies aimed at preliminarily preventing this malignant tumor. Previous studies have investigated the relationship between calcium and vitamin D intake and the incidence of bladder cancer. However, little is known about the interaction of magnesium with calcium and vitamin D.
Our current purpose is to invetigate the association between magnesium intake and bladder cancer incidence and mortality using data from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial prospective cohort. The PLCO is a well characterized and diverse study population with large number of cancer cases that would provide ample power.
Our current purpose is to invetigate the association between magnesium intake and bladder cancer incidence and mortality using data from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial prospective cohort. The PLCO is a well characterized and diverse study population with large number of cancer cases that would provide ample power.
Aims
To investigate the association between magnesium intake and bladder cancer incidence and mortality using data from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial prospective cohort.
Collaborators
zongzhe Li
Department of Urology, Institute of Urology, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu,610041, Sichuan Province, China